SBIR Phase I: Single Cell Reporter Gene Assay for Hormone Receptors

SBIR 第一阶段：激素受体的单细胞报告基因测定

• 批准号: 9960154
• 负责人: Jan Trnovsky
• 金额: $ 10万
• 依托单位: ONE CELL SYSTEMS, INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-01-01 至 2000-06-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=9960154&HistoricalAwards=false
• 关键词: SBIR; Phase; Single; Cell; Reporter

This Small Business Innovation Research Phase I project aims to develop a sensitive, high throughput reporter gene assay by combining gel microdrop encapsulation technology and fluorescence activated cell sorting with a secreted enzyme capture and detection format. Reporter gene assays are used to study eukaryotic gene expression essential for the development of higher organisms. Although there have been significant developments in reporter gene assays, an assay which provides high sensitivity, high throughput and single cell resolution is still needed. Frequently, gene products may be difficult to detect due to low abundance or instability. In addition, many potential therapeutic molecules that modulate transcription, exhibit weak target binding affinities, resulting in low reporter gene expression. The proposed assay will permit detection of a wide range of signal intensities from single, transfected cells which can be isolated for subsequent cloning. Phase I studies will use a model system to identify agonists to nuclear hormone receptors, which are regulatory switches that control diverse cellular processes in higher eukaryotes. The proposed assay will facilitate drug discovery by permitting rapid screening of combinatorial chemistry or natural product libraries against nuclear hormone receptors.The proposed assay will provide a rapid, high throughput method for screening large libraries of compounds for potential therapeutic molecules. Therapeutics is estimated to be a $100 billion market worldwide.

这个小企业创新研究I期项目旨在通过将凝胶微滴封装技术和荧光激活细胞分选与分泌酶捕获和检测形式相结合，开发一种灵敏的高通量报告基因检测方法。 报告基因分析用于研究高等生物发育所必需的真核基因表达。 尽管在报道基因测定中已经有了显著的发展，但是仍然需要提供高灵敏度、高通量和单细胞分辨率的测定。 通常，基因产物可能由于丰度低或不稳定而难以检测。 此外，许多调节转录的潜在治疗分子表现出弱的靶标结合亲和力，导致低报告基因表达。 所提出的测定将允许检测来自单个转染细胞的宽范围的信号强度，所述单个转染细胞可以被分离用于随后的克隆。 I期研究将使用模型系统来识别核激素受体的激动剂，核激素受体是控制高等真核生物中不同细胞过程的调节开关。 所提出的分析将通过允许快速筛选针对核激素受体的组合化学或天然产物库来促进药物发现。所提出的分析将提供用于筛选潜在治疗分子的化合物的大库的快速、高通量方法。 据估计，全球治疗药物市场将达到1000亿美元。